NEET-PG 2012 Practice Questions

Q: Berksonian bias is a type of ?

Selection bias. ***Selection bias*** - **Berkson's bias** is a form of **selection bias** that arises in studies conducted using hospital data. - It occurs when the probability of admission to a hospital or inclusion in a study is conditional on both exposure and disease status, leading to a **flawed association** between them. *Interviewer bias* - **Interviewer bias** is a type of **information bias** where the interviewer's expectations or knowledge about the study or participants influence the way information is sought or recorded. - This typically affects the **data collection process** and not the selection of participants. *Information bias* - **Information bias** is a broad category of biases that arise from **systematic errors in measurement** or classification of exposure or disease. - While Berkson's bias can lead to misinformation, its root cause is in how subjects are selected, not how data on those subjects is collected after selection. *Recall bias* - **Recall bias** is a type of **information bias** where there are systematic differences in the way participants **recall past events or exposures**. - It is particularly common in **case-control studies** where individuals with a disease may remember exposures differently than healthy controls.

Q: What is the term for the time between infection and maximum infectivity?

Generation time. ***Generation time*** - This is the **time interval** between receipt of infection by a host and the moment of **maximum infectivity** of that same host. - It is a crucial parameter in epidemiology for understanding **disease transmission dynamics** and the speed at which an epidemic can spread. *Incubation period* - This refers to the time from **exposure to an infectious agent** until the **onset of symptoms**. - It does not directly account for the timing of viral shedding or peak infectivity. *Serial interval* - This is the time between **symptom onset in a primary case** and **symptom onset in a secondary case** it infects. - While related to transmission, it focuses on symptomatic presentation rather than peak infectivity. *Communicable period* - This is the time during which an infected individual is **capable of transmitting** the infectious agent to others. - It represents the entire duration of potential transmission, not specifically the peak infectivity.

Q: Which cancer type has the most effective screening procedure?

Cervical Cancer. ***Cervical Cancer*** - **Pap smear and HPV testing** represent the most effective cancer screening program, with proven reduction of **>70% in cervical cancer incidence and mortality**. - Screening detects **pre-cancerous lesions (CIN)** during the long latent period, allowing for effective intervention before cancer develops. - Well-established guidelines with high sensitivity, specificity, and cost-effectiveness make it a **public health success story**. - Particularly relevant in Indian context where cervical cancer burden is high and screening programs are being expanded. *Colon Cancer* - **Colonoscopy** and **fecal occult blood testing (FOBT)** are highly effective, allowing direct visualization and removal of precancerous polyps. - While very effective with proven mortality reduction, screening uptake is lower and the procedure is more invasive than cervical cancer screening. - Effectiveness is comparable but cervical cancer screening has achieved greater population-level impact historically. *Prostate Cancer* - Screening with **PSA (prostate-specific antigen) testing** and **digital rectal exam (DRE)** is controversial due to potential for **overdiagnosis and overtreatment** of indolent cancers. - Impact on overall mortality reduction is debated, and it doesn't prevent cancer through detection of precancerous lesions like cervical/colon cancer screening. *Gastric Cancer* - **Gastric cancer screening** is not routinely recommended in most countries including India due to lower prevalence and lack of a highly effective, non-invasive screening method. - **Endoscopy** can detect gastric cancer but is typically performed in symptomatic individuals or high-risk populations (e.g., Japan, Korea), not as a general population screening tool.

Q: Which vaccine is used to prevent cholera?

WC-rBS. ***WC-rBS*** * **WC-rBS** stands for **whole-cell, recombinant B subunit** vaccine, also known as **Dukoral**. * It is an **oral inactivated vaccine** containing killed *Vibrio cholerae* O1 bacteria and the recombinant B subunit of the cholera toxin, providing immunity against cholera. * **WC-rBS is the WHO-prequalified cholera vaccine** widely used in India and recommended for travellers and in epidemic settings. * It provides protection against both O1 and O139 serogroups and offers some cross-protection against ETEC (enterotoxigenic *E. coli*). *CVD 103-HgR* * **CVD 103-HgR** (commercially known as **Vaxchora**) is an **oral live-attenuated cholera vaccine** approved by the FDA. * It is a genetically modified *Vibrio cholerae* O1 Inaba strain with deleted cholera toxin genes. * While this is also a cholera vaccine, **it is primarily used in the United States** and is not the standard vaccine used in India or recommended by WHO for mass vaccination campaigns. * In the Indian context and for NEET-PG examinations, **WC-rBS (Dukoral) is the recognized cholera vaccine**. *Ty21a* * **Ty21a** is an **oral live-attenuated vaccine** used to prevent **typhoid fever**. * It is specifically designed to target *Salmonella Typhi* bacteria, not *Vibrio cholerae*. *None of the options* * This option is incorrect because WC-rBS is the well-established and WHO-recommended vaccine for the prevention of cholera in the Indian context.

Q: What is the concentration of type 3 virus in the trivalent oral polio vaccine?

600,000 TCID 50. ***600,000 TCID 50*** - The **trivalent oral polio vaccine (tOPV)** traditionally contained specific concentrations of each serotype: **type 1 (1,000,000 TCID50/dose)**, **type 2 (100,000 TCID50/dose)**, and **type 3 (600,000 TCID50/dose)**. - Type 3 poliovirus requires a **higher concentration (600,000 TCID50)** compared to type 2 to achieve adequate immunogenicity and protection. - The **World Health Organization (WHO)** established these specific formulations for tOPV to ensure optimal efficacy and safety for each serotype. *100,000 TCID 50* - This is the concentration of **type 2 poliovirus** in tOPV, not type 3. - Due to the **global eradication of wild poliovirus type 2** by 2015, tOPV was replaced with bivalent OPV (bOPV) containing only types 1 and 3 in routine immunization programs. *400,000 TCID 50* - This concentration does not correspond to any standard poliovirus serotype in the traditional trivalent oral polio vaccine. - This value falls between type 2 (100,000) and type 3 (600,000) concentrations but is not used. *300,000 TCID 50* - This concentration is not the standard for any poliovirus serotype in the traditional trivalent oral polio vaccine. - Each serotype has a **distinct, empirically determined concentration** to achieve optimal immunity while minimizing adverse effects.

Q: Which complement proteins are formed in the liver?

C2, C4. ***C2, C4*** - While **all complement proteins (C1-C9) are primarily synthesized in the liver**, this question (NEET PG 2012) expects this as the answer based on the context of **classical pathway activation**. - **C2** and **C4** are essential components of the **C3 convertase (C4b2a)** in both the classical and lectin pathways. - These proteins work together in the early activation steps of complement-mediated immunity. - **Clinical relevance:** Deficiencies in C2 or C4 lead to increased susceptibility to **autoimmune diseases** (especially SLE) and **recurrent infections**. *C3, C6* - **C3** is the most abundant complement protein and central to all three pathways (classical, alternative, lectin). - **C6** is part of the membrane attack complex (MAC: C5b-C6-C7-C8-C9). - Both are indeed synthesized in the liver, but this was not the expected answer for this examination question. *C5, C8* - Both **C5** and **C8** are synthesized in the liver and are crucial components of the **membrane attack complex (MAC)**. - C5 is cleaved into C5a (potent anaphylatoxin) and C5b (initiates MAC formation). - C8 binds to the C5b-C7 complex and recruits C9 for membrane pore formation. *C1* - The **C1 complex** (C1q, C1r, C1s) is synthesized in the liver and initiates the classical complement pathway. - C1q recognizes antibody-antigen complexes (IgG or IgM bound to antigen). - **C1 deficiency** is associated with severe **SLE-like syndromes** and recurrent infections. **Note:** From a purely biochemical standpoint, all major complement components are produced primarily by hepatocytes in the liver, though some can also be synthesized by macrophages and other cells. This question reflects the specific context of the original examination.

Q: ER positive status in carcinoma breast indicates?

Prognosis. ***Prognosis*** - **ER positive status** in breast cancer indicates a better prognosis, as these tumors often respond well to hormone therapy [1][2]. - Patients with **ER positive** breast cancer usually have a lower risk of metastasis compared to **ER negative** tumors, making the outcome more favorable [1]. *Site* - ER status does not provide information regarding the **anatomical location** of the breast cancer, as it can be present in different sites of the breast. - It primarily focuses on the **biologic characteristics** of the tumor rather than its site of occurrence [1]. *None* - Selecting 'None' suggests that ER positive status has no relevance, which is incorrect as it is significant for treatment and prognosis [1]. - It is a crucial indicator for deciding on **endocrine therapy**, impacting management strategies in breast cancer patients [1]. *Etiology* - ER positive status does not directly indicate the **cause** of breast cancer, as various genetic and environmental factors contribute to its development. - It mainly reflects tumor behavior and response to therapies, not the **underlying factors** that lead to the disease [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, p. 1056. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, pp. 1064-1066.

Q: Which gene mutation is commonly associated with malignant melanoma?

CDKN2A. ***CDK2A*** - CDK2A mutations are implicated in malignant melanoma as they disrupt the **cell cycle regulation**, contributing to uncontrolled cell growth [1]. - Loss of CDK2A function leads to reduced **p16INK4A**, a crucial inhibitor of cyclin-dependent kinases involved in **G1/S phase transition** [1,3]. - Germline mutations of p16 (CDKN2A) are present in 25% of melanoma-prone kindreds [2], and germline mutations in CDKN2A are associated with familial forms of melanoma [3]. *RET* - RET mutations are primarily associated with **medullary thyroid carcinoma** and **multiple endocrine neoplasia type 2**, not melanoma. - It is involved in the signaling pathways but does not have a direct link to melanoma pathogenesis. *None* - Suggesting "none" misrepresents the reality that specific mutations do occur in malignant melanoma, including **CDK2A** and **BRAF**. - This option fails to recognize the importance of genetic alterations in cancer development and progression. *N-myc* - N-myc mutations are primarily associated with **neuroblastoma** and not typically linked to malignant melanoma. - In melanoma, mutations of this gene do not play a significant role in its pathophysiology compared to another tumor suppressor gene like **CDK2A**. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Skin, pp. 1150-1151. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 297-298. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 305-306.

Q: Which of the following potassium-sparing diuretics was the first to be shown to reduce cardiac mortality in chronic heart failure patients?

Spironolactone. ***Spironolactone*** - **Spironolactone** was the first potassium-sparing diuretic shown to reduce **cardiac mortality** in patients with **chronic heart failure** in the **RALES trial** (Randomized Aldactone Evaluation Study). - Its beneficial effects in heart failure are primarily attributed to its **aldosterone receptor antagonist** properties, which counteract the harmful effects of aldosterone on the myocardium and vasculature, rather than just its diuretic effect. *Amiloride* - **Amiloride** is a potassium-sparing diuretic that works by directly inhibiting **epithelial sodium channels (ENaC)** in the collecting duct. - While it helps in potassium conservation, it has not been shown to significantly reduce cardiac mortality in chronic heart failure patients in clinical trials. *Triamterene* - **Triamterene** is another potassium-sparing diuretic that also directly inhibits **ENaC** in the collecting duct, similar to amiloride. - Like amiloride, it is used to prevent hypokalemia but lacks evidence for significant **cardiac mortality reduction** in chronic heart failure. *Eplerenone* - **Eplerenone** is a selective **aldosterone receptor antagonist**, similar to spironolactone, with fewer hormonal side effects. - While it has been shown to reduce **cardiac mortality** in chronic heart failure (e.g., in the EMPHASIS-HF trial), it was introduced later than spironolactone and was not the *first* to demonstrate this benefit.

Q: Which medication is commonly used in heart failure that also has aldosterone antagonistic properties?

Spironolactone. ***Spironolactone*** - **Spironolactone** is a **potassium-sparing diuretic** that acts as a **competitive antagonist of aldosterone** receptors, primarily in the collecting ducts of the kidneys. - This action leads to increased excretion of sodium and water, and retention of potassium, which is beneficial in **heart failure** by reducing fluid overload and mitigating the detrimental effects of aldosterone on cardiac remodeling. *Carvedilol* - **Carvedilol** is a **beta-blocker** with additional **alpha-1 blocking** properties, commonly used in heart failure to reduce heart rate, blood pressure, and myocardial oxygen demand. - It does not possess significant aldosterone antagonistic properties. *Sacubitril/Valsartan* - **Sacubitril/Valsartan** is an **angiotensin receptor-neprilysin inhibitor (ARNI)**. Valsartan is an **angiotensin receptor blocker (ARB)**, and sacubitril inhibits neprilysin, an enzyme that degrades natriuretic peptides. - While it modulates the **renin-angiotensin-aldosterone system (RAAS)** and is highly effective in heart failure, it does not directly antagonize aldosterone receptors. *Abiraterone* - **Abiraterone** is an **androgen-biosynthesis inhibitor** used in the treatment of **prostate cancer**. - Its primary mechanism involves inhibiting **CYP17**, an enzyme critical for androgen production, and it has no role in the management of heart failure or aldosterone antagonism.

Question 1

Berksonian bias is a type of ?

Accepted Answer

Selection bias

Answer

Information bias

Answer

Interviewer bias

Answer

Recall bias

Question 2

What is the term for the time between infection and maximum infectivity?

Accepted Answer

Generation time

Answer

Communicable period

Answer

Incubation period

Answer

Serial interval

Question 3

Which cancer type has the most effective screening procedure?

Accepted Answer

Cervical Cancer

Answer

Prostate Cancer

Answer

Colon Cancer

Answer

Gastric Cancer

Question 4

Which vaccine is used to prevent cholera?

Accepted Answer

WC-rBS

Answer

CVD 103-HgR

Answer

Ty21 A

Answer

None of the options

Question 5

What is the concentration of type 3 virus in the trivalent oral polio vaccine?

Accepted Answer

600,000 TCID 50

Answer

400,000 TCID 50

Answer

100,000 TCID 50

Answer

300,000 TCID 50

Question 6

Which complement proteins are formed in the liver?

Accepted Answer

C2, C4

Answer

C3, C6

Answer

C5, C8

Answer

C1

Question 7

ER positive status in carcinoma breast indicates?

Accepted Answer

Prognosis

Answer

Etiology

Answer

Site

Answer

None of the options

Question 8

Which gene mutation is commonly associated with malignant melanoma?

Accepted Answer

CDKN2A

Answer

MYCN

Answer

RET

Answer

BRAF

Question 9

Which of the following potassium-sparing diuretics was the first to be shown to reduce cardiac mortality in chronic heart failure patients?

Accepted Answer

Spironolactone

Answer

Amiloride

Answer

Triamterene

Answer

Eplerenone

Question 10

Which medication is commonly used in heart failure that also has aldosterone antagonistic properties?

Accepted Answer

Spironolactone

Answer

Carvedilol

Answer

Abiraterone

Answer

Sacubitril/Valsartan

NEET-PG 2012

Community Medicine

Microbiology

Pathology

Pharmacology